



Bioxyme

FY 2024

AGM DECK

www.bioxyme.com

BXN:ASX

 **DR
WATSON**


BREATHE LIFE SCIENCES


BLS CLINICS

CanXChange.com.au

Table of CONTENTS

1

Front Page

2

Table of Contents

3

Introduction

4

Executive
Summary

5

Australia

6

UK/EU

7

Japan

8

Revenue by
Segment & Country

9

Product Showcase

10

End.



INTRODUCTION

A NOVEL APPROACH TO HEALTHCARE EXTRAORDINARY RESULTS

Our mission is better healthcare with novel drugs and consumer products:
To treat cancer and pain with a plant, depression with a single dose of a mushroom, prevent and reduce the prevalence of these diseases through consumer lifestyle and health products.

Our focus is on innovation:
Cannabis, psilocybin and MDMA medicines, healthcare technology, and novel consumer health & lifestyle products.



Executive Summary

BREATHING NEW LIFE INTO BXN:ASX

Bioxyne (BXN:ASX) has been publicly listed since 2006, and its primary business supplying its patented PCC probiotics to the USA.

In May 2023 Bioxyne acquired Breathe Life Sciences Pty Ltd (“BLS”) in an all stock deal valued at \$36m, breathing new life into BXN.

The BLS group, founded in 2018, has operations in Australia, Japan, UK, Czechia, and France supplying B2B and B2C cannabis, mushrooms, novel foods, beauty, and consumer health products under the Breathe Life Sciences and Dr Watson brands to both pharmaceutical and wellness industry.



BLS Australia

OUT WITH THE OLD, IN WITH THE NEW (PHARMACEUTICALS)

- B2B wholesale of starting materials, APIs, and manufactured medicines under our brands
- B2C supply of unregistered prescription drugs via special access pathways - BLS CLINICS working with Instant Scripts, supply of Dr Watson prescription cannabis.
- Marketplace tech for the Australian Cannabis Industry (Canxchange) & pharmacy tech for chain of custody and regulatory compliance

CanXChange

EXCITING DEVELOPMENTS:

- TGA Pharmaceutical GMP certification pending, allowing large batch manufacture of prescription products including Psilocybin, MDMA, and Cannabis products.
- BLS Clinical Trials for Psilocybin and Cannabis



BLS UK & Europe

LIFE SCIENCES: MORE THAN JUST PHARMACEUTICALS

- B2B wholesale of raw materials (Cannabis & other, for novel foods & wellness industry), APIs, and Dr Watson branded products. Clients include AMAZON, Holland & Barrett, VPZ, LUSH.
- B2C online sales of Dr Watson novel foods (CBD), consumer health and lifestyle products.
- White label manufacturing for B2B clients (Manchester, UK, and Prague, Czechia)

EXCITING DEVELOPMENTS:

- Dr Watson Website Sales up >~100% yoy
- Business expansion & growth opportunity in Plant Based foods



BLS Japan

花より団子

HANA YORI DANGO

- One of only few companies capable of importing cannabis derived materials into Japan.
- B2B wholesale of raw materials ~60% gross margin 
- B2C online sales of Dr Watson novel foods (CBD), consumer health and lifestyle products ~85% gross margin
- White label manufacturing for B2B clients in Japan ~70% gross margin 

EXCITING DEVELOPMENTS:


- Green Zone Japan & Midori No Wa project, working with Epileptic kids and families. BLS has been a sponsor and supplier of CBD to the project.



Revenue % of Total by Business Segment - Forecast

PRESCRIPTION DR WATSON PRODUCTS KEY GROWTH DRIVER

WL Manufacturing
6.9%




Health Products Dr Watson
10.4%

B2B APIs/ Materials
42.4%

Prescription Products Dr Watson
40.3%

USA
12.8%

Japan
15.4%





Australia
41%

UK/EU
30.8%



Product Showcase



End.



BREATHE LIFE SCIENCES



BLS CLINICS

CanXChange.com.au



FY 2024 AGM DECK

www.bioxyme.com

BXN:ASX